WEST

Generate Collection | Print

Search Results - Record(s) 1 through 10 of 10 returned.

☐ 1. Document ID: US 6511676 B1

L2: Entry 1 of 10 File: USPT Jan 28, 2003

US-PAT-NO: 6511676
DOCUMENT-IDENTIFIER: US 6511676 B1

TITLE: Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes

DATE-ISSUED: January 28, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Boulikas; Teni	Palo Alto	CA	94306	

US-CL-CURRENT: 424/450; 264/4.1, 264/4.3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc | Image

☐ 2. Document ID: US 6322810 B1

L2: Entry 2 of 10 File: USPT Nov 27, 2001

US-PAT-NO: 6322810
DOCUMENT-IDENTIFIER: US 6322810 B1

TITLE: Materials and methods for making improved micelle compositions

DATE-ISSUED: November 27, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alkan-Onyuksel; Hayat	Western Springs	IL	60558	
Rubinstein; Israel	Highland Park	IL	60035	

US-CL-CURRENT: 424/450; 424/1.21, 424/812, 424/9.321, 424/9.51, 424/94.3, 428/402.2, 436/829, 514/21, 514/937

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc | Image

☐ 3. Document ID: US 6217886 B1

L2: Entry 3 of 10 File: USPT Apr 17, 2001

US-PAT-NO: 6217886
DOCUMENT-IDENTIFIER: US 6217886 B1

TITLE: Materials and methods for making improved micelle compositions

DATE-ISSUED: April 17, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Onyuksel; Hayat	Western Springs	IL		
Rubinstein; Israel	Highland Park	IL		

US-CL-CURRENT: 424/401; 264/4.1, 264/4.3, 264/4.6, 424/1.21, 424/450, 424/9.321, 424/9.51, 514/2, 514/21, 514/937

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw. Desc | Image

---

☐ 4. Document ID: US 6177079 B1

L2: Entry 4 of 10 File: USPT Jan 23, 2001

US-PAT-NO: 6177079
DOCUMENT-IDENTIFIER: US 6177079 B1

TITLE: Antagonists of interleukin-15

DATE-ISSUED: January 23, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Grabstein; Kenneth H.	Mercer Island	WA		
Pettit; Dean K.	Seattle	WA		
Paxton; Raymond J.	Bellevue	WA		

US-CL-CURRENT: 424/152.1; 424/130.1, 424/133.1, 424/141.1, 424/145.1, 530/388.1, 530/388.23, 530/389.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWMC | Draw. Desc | Image

---

☐ 5. Document ID: US 6168783 B1

L2: Entry 5 of 10 File: USPT Jan 2, 2001

US-PAT-NO: 6168783
DOCUMENT-IDENTIFIER: US 6168783 B1

TITLE: Antagonists of interleukin-15

DATE-ISSUED: January 2, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Grabstein; Kenneth H.	Mercer Island	WA		
Pettit; Dean K.	Seattle	WA		
Paxton; Raymond J.	Bellevue	WA		

US-CL-CURRENT: 424/85.1; 424/85.2, 530/300, 530/350

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

---

☐ 6. Document ID: US 6165466 A

L2: Entry 6 of 10 File: USPT Dec 26, 2000

US-PAT-NO: 6165466
DOCUMENT-IDENTIFIER: US 6165466 A

TITLE: Antagonists of interleukin-15

DATE-ISSUED: December 26, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Grabstein; Kenneth H.	Mercer Island	WA		
Pettit; Dean K.	Seattle	WA		
Paxton; Raymond J.	Bellevue	WA		

US-CL-CURRENT: 424/145.1; 424/158.1, 424/172.1, 424/173.1, 530/388.23

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

---

☐ 7. Document ID: US 6013480 A

L2: Entry 7 of 10 File: USPT Jan 11, 2000

US-PAT-NO: 6013480
DOCUMENT-IDENTIFIER: US 6013480 A

TITLE: Antagonists of interleukin-15

DATE-ISSUED: January 11, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Grabstein; Kenneth H.	Mercer Island	WA		
Pettit; Dean K.	Seattle	WA		
Paxton; Raymond J.	Bellevue	WA		

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 536/23.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw Desc | Image

☐ 8. Document ID: US 5795966 A

L2: Entry 8 of 10 File: USPT Aug 18, 1998

US-PAT-NO: 5795966
DOCUMENT-IDENTIFIER: US 5795966 A

TITLE: Antagonists of interleukin-15

DATE-ISSUED: August 18, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Grabstein; Kenneth H.	Mercer Island	WA	98040	
Pettit; Dean K.	Seattle	WA	98112	
Paxton; Raymond J.	Bellevue	WA	98006	

US-CL-CURRENT: 530/388.23; 424/158.1, 435/326, 435/328, 435/335, 435/346, 435/352

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw Desc | Image

☐ 9. Document ID: US 5660824 A

L2: Entry 9 of 10 File: USPT Aug 26, 1997

US-PAT-NO: 5660824
DOCUMENT-IDENTIFIER: US 5660824 A

TITLE: Muscle trophic factor

DATE-ISSUED: August 26, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Grabstein; Kenneth H.	Mercer Island	WA	98040	
Quinn; LeBris S.	Seattle	WA	98136	
Troutt; Anthony B.	Brier	WA	98036	

US-CL-CURRENT: 424/85.2; 530/351

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw Desc | Image

☐ 10. Document ID: WO 9832466 A1 JP 2001508783 W AU 9857737 A EP 921817 A1 EP 921817 B1 DE 69800640 E

L2: Entry 10 of 10 File: DWPI Jul 30, 1998

DERWENT-ACC-NO: 1998-427686
DERWENT-WEEK: 200142

TITLE: Process for attachment of poly:ethylene glycol to target substrates - by reacting halogenated PEG with substrate e.g. peptide, nucleic acid, non-steroidal hormone, antibiotic or liposome

INVENTOR: FISHER, D; FRANCIS, G E ; MALIK, F

PRIORITY-DATA: 1997GB-0008055 (April 22, 1997), 1997GB-0001800 (January 29, 1997), 1997GB-0001804 (January 29, 1997), 1997GB-0004653 (March 6, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9832466 A1	July 30, 1998	E	064	A61K047/48
JP 2001508783 W	July 3, 2001		055	A61K047/48
AU 9857737 A	August 18, 1998		000	A61K047/48
EP 921817 A1	June 16, 1999	E	000	A61K047/48
EP 921817 B1	March 28, 2001	E	000	A61K047/48
DE 69800640 E	May 3, 2001		000	A61K047/48

INT-CL (IPC): A61 K 38/00; A61 K 38/22; A61 K 38/46; A61 K 47/48

End of Result Set

L5: Entry 2 of 2 File: USPT Dec 10, 1991

DOCUMENT-IDENTIFIER: US 5071964 A
TITLE: Protein micelles

Brief Summary Text (7):
The adhesion protein micelles of the invention can further be used for the treatment of medical conditions characterized by the presence of an excess of activated T-cells by administering LFA-3 micelles in a physiologically compatible buffer to a patient to achieve a bloodstream concentration of LFA-3 effective to inhibit the binding of the activated T-cells to other cells in the patient; the resultant bloodstream concentration of LFA-3 is preferably 0.4 to 40 nM of LFA-3. Disease states characterized by the presence of an excess of activated T-cells include multiple sclerosis, sarcoidosis, juvenile type diabetes mellitus, systemic lupus ery.thmatosis, thyroiditis, rheumatoid arthritis, ankyloses spondylitis, primary biliary cirrhosis, autoimmune hemolytic anemia, immune thrombocytopenia purpura, myesthenia gravis, allograft rejection and graft versus host disease.

Detailed Description Text (31):
mLFA-3 micelles alone have no effect on PBL-T proliferation, but they can induce proliferation of PBL-T in the presence of submitogenic concentrations of anti-CD2 MAb's. The combination of mLFA-3 micelles (40 nM) with CD2 MAb was found to be strongly mitogenic for peripheral blood mononuclear cells (PBMC) from all donors tested (Table 7). This response was usually (9 of 10 donors) seen in the absence of exogenous IL-2, although phorbol myristate acetate (PMA) was still required for a maximal response. Proliferation induced by the combination of mLFA-3 micelles and CD2.1 MAb was generally lower than that obtained with phytohemagglutanin (PHA), while the combination of mLFA-3, CD2.1 and PMA resulted in greater thymidine incorporation than PHA alone by up to two fold in some donors. The combination of mLFA-3 and CD2.1 MAb was also mitogenic for nylon wool enriched T-cells (Table 8).

Detailed Description Text (37):
The proliferative response to mLFA-3 with CD2.1 MAb was completely blocked by both anti-LFA-3 MAb's and the 9.6 MAb. The 9.6 MAb blocks mLFA-3 binding to CD2 but is usually not comitogenic with CD2.1 MAb (Table 9). The response to mLFA-3 with CD2.1 MAb was also blocked by CD25 (anti-IL 2 receptor p55 chain) MAb suggesting that it is IL 2 dependent. The mitogenic response of PBMC or PBL-T to mLFA-3 with CD2.1 MAb was accompanied by aggregation of cells within 16 hours. These clusters could not have been the result of passive agglutination of cells by mLFA-3 micelles, because clusters were not seen with mLFA-3 in the absence of CD2.1 MAb.

WEST

Generate Collection Print

L1: Entry 35 of 47 File: USPT Jun 23, 1998

DOCUMENT-IDENTIFIER: US 5770570 A
TITLE: Method of delivering a vasoactive intestinal polypeptide, an encapsulated vasoactive intestinal polypeptide, and a method of making the encapsulated vasoactive intestinal polypeptide

Detailed Description Text (90):
Treatment of (Tyr.sup.10 -.sup.125 I)VIP-liposome complexes with 25 mM EDTA, 1 mM HCl, or 1M NaCl caused little or no release of the bound peptide, as shown in Table 2. At alkaline pH (1mM NaOII), a small but significant proportion (16) of the bound radioactivity was reproducibly released. Dissolution of the liposomes with SDS produced near-complete peptide release into the supernatant, reflecting, presumably, uptake of the peptide into mixed detergent-lipid micelles.

WEST

Generate Collection Print

L1: Entry 41 of 47 File: USPT Dec 10, 1991

DOCUMENT-IDENTIFIER: US 5071964 A
TITLE: Protein micelles

Detailed Description Text (31):
mLFA-3 micelles alone have no effect on PBL-T proliferation, but they can induce proliferation of PBL-T in the presence of submitogenic concentrations of anti-CD2 MAb's. The combination of mLFA-3 micelles (40 nM) with CD2 MAb was found to be strongly mitogenic for peripheral blood mononuclear cells (PBMC) from all donors tested (Table 7). This response was usually (9 of 10 donors) seen in the absence of exogenous IL-2, although phorbol myristate acetate (PMA) was still required for a maximal response. Proliferation induced by the combination of mLFA-3 micelles and CD2.1 MAb was generally lower than that obtained with phytohemagglutanin (PHA), while the combination of mLFA-3, CD2.1 and PMA resulted in greater thymidine incorporation than PHA alone by up to two fold in some donors. The combination of mLFA-3 and CD2.1 MAb was also mitogenic for nylon wool enriched T-cells (Table 8).

Detailed Description Text (37):
The proliferative response to mLFA-3 with CD2.1 MAb was completely blocked by both anti-LFA-3 MAb's and the 9.6 MAb. The 9.6 MAb blocks mLFA-3 binding to CD2 but is usually not comitogenic with CD2.1 MAb (Table 9). The response to mLFA-3 with CD2.1 MAb was also blocked by CD25 (anti-IL 2 receptor p55 chain) MAb suggesting that it is IL 2 dependent. The mitogenic response of PBMC or PBL-T to mLFA-3 with CD2.1 MAb was accompanied by aggregation of cells within 16 hours. These clusters could not have been the result of passive agglutination of cells by mLFA-3 micelles, because clusters were not seen with mLFA-3 in the absence of CD2.1 MAb.

WEST Search History

DATE: Thursday, March 06, 2003

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L6	L1 and (ischemia)	2	L6
L5	L1 and (multiple adj1 sclerosis)	2	L5
L4	L1 and stroke	1	L4
L3	L1 and parkinson$	1	L3
L2	L1 and peg	10	L2
L1	micelle$ same (vip or glucagon or secretin or IL$)	47	L1

END OF SEARCH HISTORY